SEARCH

SEARCH BY CITATION

References

  • 1
    Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001; 22:63340.
  • 2
    Mavilio D, Lombardo G, Benjamin J et al. Characterization of CD56/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci USA 2005; 102:288691.
  • 3
    Caligiuri M. Human natural killer cells. Blood 2008; 112:4619.
  • 4
    Hayakawa Y, Huntington ND, Nutt SL, Smyth MJ. Functional subsets of mouse natural killer cells. Immunol Rev 2006; 214:4755.
  • 5
    Wilk E, Kalippke K, Buyny S, Schmidt RE, Jacobs R. New aspects of NK cell subset identification and inference of NK cells’ regulatory capacity by assessing functional and genomic profiles. Immunobiology 2008; 213:27183.
  • 6
    Nagler A, Lanier LL, Cwirla S, Phillips JH. Comparative studies of human FcRIII-positive and negative natural killer cells. J Immunol 1989; 143:318391.
  • 7
    Jacobs R, Hintzen G, Kemper A, Beul K, Kempf S, Behrens G, Sykora KW, Schmidt RE. CD56bright NK cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells. Eur J Immunol 2001; 31:31216.
  • 8
    Lanier LL. NK cell receptors. Annu Rev Immunol 1998; 16:35993.
  • 9
    Vitale M, Zimmer J, Castriconi R et al. Analysis of natural killer cells in TAP2-deficient patients: expression of functional triggering receptors and evidence for the existence of inhibitory receptor(s) that prevent lysis of normal autologous cells. Blood 2002; 99:17239.
  • 10
    Wendt K, Wilk E, Buyny S, Schmidt RE, Jacobs R. Interleukin-21 differentially affects human natural killer cell subsets. Immunology 2007; 122:48695.
  • 11
    Campbell JJ, Qin S, Unutmaz D, Soler D, Murphy KE, Hodge MR, Wu L, Butcher EC. Unique subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire. J Immunol 2001; 166:647782.
  • 12
    Sedlmayr P, Schallhammer L, Hammer A, Wilders-Truschnig M, Wintersteiger R, Dohr G. Differential phenotypic properties of human peripheral blood CD56dim+ and CD56bright+ natural killer cell subpopulations. Int Arch Allergy Immunol 1996; 110:30813.
  • 13
    Anumanthan A, Bensussan A, Boumsell L et al. Cloning of BY55, a novel Ig superfamily member expressed on NK cells, CTL, and intestinal intraepithelial lymphocytes. J Immunol 1998; 161:278090.
  • 14
    Solomon KR, Chan M, Finberg RW. Expression of GPI-anchored complement regulatory proteins CD55 and CD59 differentiates two subpopulations of human CD56+ CD3 lymphocytes (NK cells). Cell Immunol 1995; 165:294301.
  • 15
    Hanna J, Bechtel P, Zhai Y, Youssef F, McLachlan K, Mandelboim O. Novel insights on human NK cells’ immunological modalities revealed by gene expression profiling. J Immunol 2004; 173:654763.
  • 16
    Wendt K, Wilk E, Buyny S, Buer J, Schmidt RE, Jacobs R. Gene and protein characteristics reflect functional diversity of CD56dim and CD56bright NK cells. J Leukoc Biol 2006; 80:152941.
  • 17
    Fehniger TA, Shah MH, Turner MJ et al. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol 1999; 162:451120.
  • 18
    Ferlazzo G, Thomas D, Lin SL, Goodman K, Morandi B, Muller WA, Moretta A, Münz C. The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol 2004; 172:145562.
  • 19
    Fehniger TA, Cooper MA, Nuovo GJ, Cella M, Facchetti F, Colonna M, Caligiuri MA. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 2003; 101:30527.
  • 20
    Ferlazzo G, Münz C. NK cell compartments and their activation by dendritic cells. J Immunol 2004; 172:13339.
  • 21
    Vitale M, Bottino C, Sivori S et al. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med 1998; 187:206572.
  • 22
    Saito S, Nakashima A, Myojo-Higuma S, Shiozaki A. The balance between cytotoxic NK cells and regulatory NK cells in human pregnancy. J Reprod Immunol 2008; 77:1422.
  • 23
    Koopman LA, Kopcow HD, Rybalov B et al. Human decidual natural killer cells are a unique NK subset with immunomodulatory potential. J Exp Med 2003; 198:120112.
  • 24
    Vitale M, Della Chiesa M, Carlomagno S, Romagnani C, Thiel A, Moretta L, Moretta A. The small subset of CD56brightCD16 natural killer cells is selectively responsible for both proliferation and interferon-γ production upon interaction with dendritic cells. Eur J Immunol 2004; 34:171522.
  • 25
    Dalbeth N, Gundle R, Davies RJ, Lee YC, McMichael AJ, Callan MF. CD56bright NK cells are enriched at inflammatory sites and can engage with monocytes in a reciprocal program of activation. J Immunol 2004; 173:641826.
  • 26
    André P, Spertini O, Guia S et al. Modification of P-selectin glycoprotein ligand-1 with a natural killer cell-restricted sulphated lactosamine creates an alternate ligand for L-selectin. Proc Natl Acad Sci U S A 2000; 97:34005.
  • 27
    Chan A, Hong DL, Atzberger A et al. CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts. J Immunol 2007; 179:8994.
  • 28
    Romagnani C, Juelke K, Falco M et al. CD56brightCD16 killer Ig-like receptor NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation. J Immunol 2008; 178:494755.
  • 29
    Ouyang Q, Baerlocher G, Vulto I, Lansdorp PM. Telomere length in human natural killer cell subsets. Ann N Y Acad Sci 2007; 1106:24052.
  • 30
    Keskin DB, Allan DS, Rybalov B, Andzelm MM, Stern JN, Kopcow HD, Koopman LA, Strominger JL. TGFβ promotes conversion of CD16+ peripheral blood NK cells into CD16 NK cells with similarities to decidual NK cells. Proc Natl Acad Sci USA 2007; 104:337883.
  • 31
    Carson W, Caligiuri M. Natural killer cell subsets and development. Methods 1996; 9:32743.
  • 32
    Zimmer J, Bausinger H, Andrès E, Donato L, Hanau D, Hentges F, Moretta A, De La Salle H. Phenotypic studies of natural killer cell subsets in human transporter associated with antigen processing deficiency. PLoS ONE 2007; 2:e1033.
  • 33
    Villa-Forte A, De La Salle H, Fricker D, Hentges F, Zimmer J. HLA class I deficiency syndrome mimicking Wegener’s granulomatosis. Arthritis Rheum 2008; 58:257982.
  • 34
    Cac NC, Ballas ZK. Recalcitrant warts, associated with natural killer cell dysfunction, treated with systemic IFN-α. J Allergy Clin Immunol 2006; 118:5268.
  • 35
    Saraste M, Irjala H, Airas L. Expansion of CD56bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta. Neurol Sci 2007; 28:1216.
  • 36
    Bielekova B, Catalfamo M, Reichert-Scrivner S et al. Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Rα -targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A 2006; 103:59416.
  • 37
    Li Z, Lim WK, Mahesh SP, Liu B, Nussenblatt RB. Cutting edge: in vivo blockade of human IL-2 receptor induces expansion of CD56bright regulatory NK cells in patients with active uveitis. J Immunol 2005; 174:518791.
  • 38
    Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol 2008; 9:50310.
  • 39
    Kubo T, Sato K, Kobayashi D, Motegi A, Kobayashi O, Takeshita S, Nonoyama S. A case of HHV-6 associated acute necrotizing encephalopathy with increase of CD56bright NK cells. Scand J Infect Dis 2006; 38:11225.
  • 40
    Shibata F, Toma T, Wada T et al. Skin infiltration of CD56brightCD16 natural killer cells in a case of X-SCID with Omenn syndrome-like manifestations. Eur J Haematol 2007; 79:8185.
  • 41
    Golden-Mason L, Madrigal-Estebas L, McGrath E, Conroy MJ, Ryan EJ, Hegarty JE, O’Farrelly C, Doherty DG. Altered natural killer cell subset distributions in resolved and persistent hepatitis C virus infection following single source exposure. Gut 2008; 57:11218.
  • 42
    Barcelos W, Sathler-Avelar R, Martins-Filho OA et al. Natural killer cell subpopulations in putative resistant individuals and patients with active Mycobacterium tuberculosis infection. Scand J Immunol 2008; 68:92102.
  • 43
    Schepis D, Gunnarsson I, Eloranta MJ, Lampa J, Jacobson SH, Kärre K, Berg L. Increased proportion of CD56bright natural killer cells in active and inactive systemic lupus erythematosus. Immunology 2009; 126:1406.
  • 44
    Gumá M, Angulo A, Vilches C, Gómez-Lozano N, Malats N, López-Botet M. Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood 2004; 104:366471.
  • 45
    Gumá M, Cabrera C, Erkizia I, Bofill M, Clotet B, Ruiz L, López-Botet M. Human cytomegalovirus infection is associated with increased proportions of NK cells that express the CD94/NKG2C receptor in aviremic HIV-1-positive patients. J Infect Dis 2006; 194:3841.
  • 46
    Mela CM, Burton CT, Imami N, Nelson M, Steel A, Gazzard BG, Gotch FM, Goodier MR. Switch from inhibitory to activating NKG2 receptor expression in HIV-1 infection: lack of reversion with highly active antiretroviral therapy. AIDS 2005; 19:17619.
  • 47
    Kusumi M, Yamashita T, Fujii T, Nagamatsu T, Kozuma S, Taketani Y. Expression patterns of lectin-like natural killer receptors, inhibitory CD94/NKG2A, and activating CD94/NKG2C on decidual CD56bright natural killer cells differ from those on peripheral CD56dim natural killer cells. J Reprod Immunol 2006; 70:3342.
  • 48
    Ottaviani C, Nasorri F, Bedini C, De Pita O, Girolomoni G, Cavani A. CD56brightCD16 NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation. Eur J Immunol 2006; 36:11828.
  • 49
    Pridgeon C, Lennon GP, Pazmany L, Thompson RN, Christmas SE, Moots RJ. Natural killer cells in the synovial fluid of rheumatoid arthritis patients exhibit a CD56bright, CD94bright, CD158negative phenotype. Rheumatology 2003; 42:8708.
  • 50
    Katchar K, Söderström K, Wahlstrom J, Eklund A, Grunewald J. Characterisation of natural killer cells and CD56+ T-cells in sarcoidosis patients. Eur Respir J 2005; 26:7785.
  • 51
    Hak L, Mysliwska J, Wieckiewicz J, Szyndler K, Trzonkowski P, Siebert J, Mysliwski A. NK cell compartment in patients with coronary heart disease. Immun Ageing 2007; 4:3.
  • 52
    Scordamaglia F, Balsamo M, Scordamaglia A, Moretta A, Mingari MC, Canonica GW, Moretta L, Vitale M. Perturbations of natural killer cell regulatory functions in respiratory allergic diseases. J Allergy Clin Immunol 2008; 121:47985.
  • 53
    Villanueva J, Lee S, Giannini EH, Graham TB, Passo MH, Filipovich A, Grom AA. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther 2005; 7:R307.